These NKG2D CAR engineered primary NK cells through retroviral transduction showed significantly enhanced in vitro cytotoxicity against a variety of solid tumor cell lines that express NKG2D ligands MICA/B such as the osteosarcoma cell lines U-2 OS, MG-36, HOS, the prostate carcinoma cell lines DU 145 and PC-3, and the rhabdomyosarcoma cell line RH36 (196) and significantly reduced tumor burden in osteosarcoma xenografted NSG mice compared to mock NK cells (196). This evidence concerns the gene KLRK1 and rhabdomyosarcoma.